Physician profile
Deepak Mangla
NPI 1942648902
$13,974.23
in general payments reported to CMS, 2019-2025
13 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,221 · 2021: $27.28 · 2022: $311 · 2023: $5,248 · 2024: $2,732 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,640 · Food and Beverage: $1,482 · Travel and Lodging: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,640.00 |
| Food and Beverage | $1,482.30 |
| Travel and Lodging | $1,292.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $12,484.37 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $596.80 | 2021-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $242.22 | 2024 | Yutiq, Iluvien |
| Genentech, INC. | $198.97 | 2019 | |
| Astellas Pharma US INC | $115.31 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $106.82 | 2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Biogen, INC. | $87.14 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $36.56 | 2023 | Syfovre |
| Coherus Oncology, INC. | $31.53 | 2023 | |
| Lkc Technologies, INC. | $19.23 | 2025 | |
| Sandoz INC. | $18.99 | 2024 | Cimerli |
| Biotissue Holdings INC. | $18.33 | 2025 | |
| Bausch & Lomb Americas INC. | $17.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Mangla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.